Conversion from preclinical to clinical stage of Alzheimer’s disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation

  • O. Almkvist
  • K. Axelman
  • H. Basun
  • L.-O. Wahlund
  • L. Lannfelt
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


The characterisation of the borderline syndrome between normalcognitive function and Alzheimer’s disease (AD), often mentioned as MildCognitive Impairment (MCI) has been a goal for recent research, However, avariety of definitions of MCI-like syndromes and the uncertainty about thefinal diagnosis have hampered progress, To overcome these problems, thepresent study will describe cognitive function in two healthy mutation carriersand two matched non-carriers of the Swedish double mutation family, duringthe time period when carriers convert to a symptomatic stage, i.e“ true pre-clinical AD, and finally into the stage when a clinical diagnosis of AD is firstpossible. The findings question the generality of common MCI concepts andthe commonly held beliefs about cognitive features in late preclinical stage of AD.


Mild Cognitive Impairment Mutation Carrier Episodic Memory White Matter Hyperintensities Full Scale Intelligence Quotient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Almkvist 0,Thoren M,SaM M,Eriksson,(1986) Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study.Psychoneuroendocrinol 11: 347–352CrossRefGoogle Scholar
  2. Almkvist 0, Basun H, Backman L, et al (1998) Mild cognitive impairment - an earlystage of Alzheimer’s disease? J Neural Transm [Suppl] 54: 21–29CrossRefGoogle Scholar
  3. American Psychiatric Association (1987) Diagnostic and statistical manual of mentadisorders, 3,d edn, rev. American Psychiatric Association, Washington, DCGoogle Scholar
  4. Axelman K., Basun H., Winblad B., Lannfelt L. (1994) A large Swedish family withAlzheimer’s disease with a codon 670/671 amyloid precursor protein mutation: aclinical and genealogical investigation. Arch Neurol 51: 1193–1197PubMedCrossRefGoogle Scholar
  5. Backman L., Forsell Y. (1994) Episodic memory functioning in a community-basedsample of very old adults with major depression:utilization of cognitive support J Abnorm Psychol 103: 361–370PubMedCrossRefGoogle Scholar
  6. Craik I.M.,Salthouse T.A. (1992) Handbook of aging and cognition. Lawrence ErlbaumHillsdale, NJGoogle Scholar
  7. Crook T, Bartus RT, Ferris SH, et al (1986) Age-associated memory impairment: proposed criteria and measures of clinical change. Report on the National institute omental health work group. Dev Neuropsychol 2: 261–276CrossRefGoogle Scholar
  8. Dureman I,Salde H (1959) Psykometriska och experimentalpsykologiska metoder forklinisk tillampning [Psychometric and experimental psychological methods for clini-cal application.Almqvist &Wiksell,Uppsala,SwedenGoogle Scholar
  9. Fabrigoule C, Rouch I, Taberly A, et al (1998) Cognitive processes in preclinical phase ofdementia. Brain 121: 135–141PubMedCrossRefGoogle Scholar
  10. Flicker C, Ferris SH, Reisberg B (1991) Mild cognitive impairment in the elderly:predictors of dementia. Neurology 41: 1006–1009PubMedCrossRefGoogle Scholar
  11. Iregren A, Gamberale F, Kjellberg A (1996) SPES: a psychological test system todiagnose environmental hazards. Neurotoxicol Teratol 18: 485--491PubMedCrossRefGoogle Scholar
  12. Kral VA (1962) Senescent forgetfulness: benign and malign. Can Med Assoc J 86: 257–2601PubMedCentralPubMedGoogle Scholar
  13. Lannfelt L, Bogdanovic N, Appelgren H, et al (1994) Amyloid precursor protein muta-tion casuses Alzheimer’s disease in a Swedish family. Neurosci Lett 168: 254–256PubMedCrossRefGoogle Scholar
  14. Lezak M (1995) Neuropsychological assessment, 3’d edn. Oxford University Press, NewYorkGoogle Scholar
  15. McKhann G., Drachman D., Folstein M., et al (1984) Clinical diagnosis of Alzheimer’sdisease: report of the NINCDS-ADRDAWork group under the auspices of Depart-ment of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34: 939–944PubMedCrossRefGoogle Scholar
  16. Mullan M, Crawford F, Axelman K, et al (1992) A pathogenic mutation for probableAlzheimer’s disease in the APP gene at the N-terminus of ~-amyloid. Nat Genet 1:345–347PubMedCrossRefGoogle Scholar
  17. Petersen RC, Smith GE, Waring SC, et al (1999) Mild cognitive impairment: clinicalcharacterization and outcome. Arch Neurol 56: 303–308PubMedCrossRefGoogle Scholar
  18. Ritchie K, Artero S, Touchon J (2001) Classification criteria for mild cognitive impair-ment: a population-based validation study. Neurology 56: 37--42PubMedCrossRefGoogle Scholar
  19. Smith PJ, Langolf GD, Goldberg J (1983) Effect of occupational exposure to elementalmercury on short-term memory. Br J Ind Med 40: 413¡ª419Google Scholar
  20. Wahlund LO, Basun H, Almkvist 0, et al (1999) A clinical follow-up of a Swedish familywith 670/671 APP mutation. Dem Geriatr Cogn Disord 10: 526–533CrossRefGoogle Scholar
  21. Wechsler D (1981) Wechsler Adult Intelligence Scale: Revised. Hartcourt BraceJovanovich, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • O. Almkvist
    • 1
    • 4
  • K. Axelman
    • 2
  • H. Basun
    • 1
  • L.-O. Wahlund
    • 1
  • L. Lannfelt
    • 3
  1. 1.Divisions of Geriatric Medicine B84Huddinge University HospitalStockholmSweden
  2. 2.Experimental Geriatrics, Karolinska Institutet Department of Clinical Neuroscience,Occupational Therapy, and Elderly Care Research (NEUROTEC)Huddinge University HospitalStockholm
  3. 3.Department of Public Health/GeriatricsUppsala University HospitalUppsalaSweden
  4. 4.Department of PsychologyStockholm UniversityStockholmSweden

Personalised recommendations